SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper
SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper
30 June 2021
SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper Download
COVID-19, the disease caused by SARS-CoV-2, is an infectious disease caused by a newly discovered coronavirus. While many of whom become infected by the disease will experience mild to moderate cold or flu-like symptoms, those with health complications – such as autoimmune diseases, asthma, heart disease and diabetes – are at risk of developing serious illness and adverse outcomes.
As of September 2021, over 228 million COVID-19 cases have been confirmed worldwide, with an estimated one in six patients experiencing complications which could be life threatening, with over £116 billion spent by the UK government alone on measures to combat the disease. This drastic spending has been mirrored across the globe, with the significant economic burden expected to be suffered for generations to come.
The whitepaper provides a brief overview of the COVID-19 pandemic, before discussing vascular abnormalities and associated complications brought on by the virus, such as multi-system disfunction, acute respiratory disease syndrome (ARDS) and hepatic, renal & cardiovascular function.
Want to know more about Randox?
Contact us or visit our homepage to view more.
Our COVID-19 Products and Services
HOME TEST
ANTIBODY TEST
TRAVEL CERTIFICATE
LABORATORY TOOLS
Vivalytic | Customer Support
Vivalytic | Customer Support
–
Molecular Diagnostics at the Point of Care
VIDEO TUTORIALS
For your support, we have compiled a series of informative video tutorials on how to install and operate the Vivalytic machine. You can use these guides to refresh your knowledge from prior training or to learn about specific procedures step by step.
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
Vivalytic Overview
SARS-CoV-2 Rapid Test
SARS-CoV-2 Pooling Test
Vivalytic Test Menu
Vivalytic | CoV Viral SARS-CoV-2 Test
Vivalytic | CoV
–
Viral SARS-CoV-2 (COVID-19) Testing
Detection of ORF1ab gene specific for SARS-CoV-2 and E gene specific for Sarbecovirus (confirmatory target)
- Detection from Biochip Technology (End-point PCR) via Nasopharyngeal and/or Oropharyngeal swab
- Detects both ORF1ab gene specific for SARS-CoV-2 and E gene specific for Sarbecovirus (confirmatory target)
- The Vivalytic CoV Viral SARS-CoV-2 test has recently received CE marketing
- Simple and easy to use analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
- Quick turnaround of 2.5 hours from sample entry to results
- Convenient 4 step process from sample entry to results. No laboratory training required
CoV is a rapid viral infection test for the detection of SARS-CoV-2 providing a clear and concise result in a timely manner direct at the point of care. Available on the Vivalytic, the CoV test cartridge detects both ORF1ab gene specific for SARS-CoV-2 and E gene specific for Sarbecovirus (confirmatory target), to report COVID-19 positive patient samples. This enables the patient to take the recommended safety precautions without delay.
Vivalytic Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.
“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
Viral Respiratory Infection Array
SARS-CoV-2 Pooling Test
Vivalytic
Vivalytic Test Menu
Vivalytic | SARS-CoV-2 Pooling Test
Vivalytic | SARS-CoV-2 Pooling Test
–
Detecting SARS-CoV-2 (COVID-19)
Detecting SARS-CoV-2 (COVID-19) from up to 5 Pooled Samples Simultaneously
- Detection from real-time PCR via Nasopharyngeal and/or Oropharyngeal swab
- Up to 5 patient samples may be pooled and added to a single cartridge targeting the E gene sequence
- The SARS-CoV-2 pooling test has recently received CE marking
- Simple and easy to use POC analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
- Rapid turnaround from sample entry to result, capable of testing up to 160 samples a day
- Convenient 4 step process from sample entry to results. No laboratory training required
SARS-CoV-2 Pooling (COVID-19) is a rapid real time PCR test cartridge, providing clear and concise results in a timely manner, direct at the point of care. This enables the patient to take the recommended safety precautions without delay. The pooling could be done at the level of a ward, medical speciality, social bubble, or group of colleagues. It has potential for use in other settings, such as pre-operative screening, schools and universities, prisons, nursing homes, primary care, and large workplaces. Sample pooling allows more people to be tested quickly using fewer testing resources.
In collaboration with Bosch, we are proud to release not only a rapid testing solution for the detection of SARS-CoV-2 (COVID-19) but an accelerated mass testing solution to effectively and efficiently monitor and detect viral infection from the offset with an aim of minimising the rise in infections globally. The new SARS-CoV-2 pooling test will allow users to test up to 160 samples a day and has sensitivity of 98% and a specificity of 100% – a world’s first! Highly sensitive assays allow for laboratories to accurately detect low positive samples, enabling for effective identification of positive COVID-19 cases in a timely manner.
Vivalytic Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.
“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
Viral Respiratory Infection Array
SARS-CoV-2 Rapid Test
Vivalytic
Vivalytic Test Menu
Vivalytic | Sexually Transmitted Infection Array
Vivalytic | Sexually Transmitted Infection Array
–
1 Sample | 1 Test | 10 Infections
Comprehensive Sexual Health Profile
- Detecting 10 bacterial, viral and protozoan infections
- Sample to answer, cartridge based molecular diagnostics at the point of care. Powered by Randox Biochip Technology
- The STI array has recently received CE marking
- Simple and easy to use analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
- Rapid turnaround time of just 2 hours from sample entry to result
- Convenient 4 step process from sample entry to results. No laboratory training required
The Sexually Transmitted Infection (STI) array is the broadest multiplex cartridge-based STI test on the market simultaneously detecting 7 bacterial, 2 viral and 1 protozoan infection for a comprehensive sexual health profile.
Globally, each day over 1 million people are exposed to an STI, many of who will not know they have an infection as many STI’s are asymptomatic whilst some individuals will display similar or overlapping symptoms, therefore co-infections may remain undiagnosed. Designed to offer a complete sexual health profile with an aim of prevention and control, the Vivalytic STI array can be used to diagnose existing infections whilst any identifying co-infections.
To find out more about the global economic burden of STIs and the impact of the COVID-19 pandemic on sexual health, download our most recent whitepaper that presents issues such as AMR, the development of super-gonorrhoea, and the challenges faced in a social and public concept due to the COVID-19 pandemic.
Vivalytic Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.
“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
Viral Respiratory Infection Array
Vivalytic Test Cartridges
Vivalytic
Vivalytic Test Menu
New 39-minute COVID test available on Randox-Bosch Vivalytic
02 October 2020
New 39-minute COVID test available on Randox-Bosch Vivalytic
- The world’s fastest PCR based SARS-CoV-2 test for the point of care delivers reliable results in 39 minutes.
- Has a sensitivity of 98 percent and a specificity of 100 percent.
- Simultaneous testing of five people with one cartridge by pooling will be available from early October.
- Work is in progress to further reduce time to result.
A rapid new coronavirus test, which provides results for Covid-19 in just 39 minutes, is now available on the Vivalytic, a point of care platform brought to market by Randox Laboratories and Bosch.
The test for detection of the SARS-CoV-2 pathogen, is currently the fastest PCR test (the gold standard of test methods) worldwide, and is predestined for decentralized use in mobile test centres at service stations or in airports, so that people who take the test can obtain a reliable result while at the testing site.
Available now in Europe, the CE-approved test, which has a sensitivity of 98 percent and a specificity of 100 percent, helps avoid time in quarantine, relieve laboratories, and make travel and work safer again.
“Rapid and accurate testing plays a crucial role in identifying cases of Covid-19 – to contain any outbreaks and limit the spread of the virus,” says Dr. Heather McMillan, Molecular R&D Manager at Randox Biosciences.
“This new rapid test will be a game-changer in the coronavirus testing landscape by allowing patients to receive their results at the point of care faster than ever before.”
Randox and Bosch launched the first rapid test for the Vivalytic analyser at the end of March, after just six weeks’ development.
As a multiplex test, it simultaneously checks samples for the SARS-CoV-2 virus as well as nine other respiratory diseases in two and a half hours, whereas the new accelerated test is exclusively for SARS-CoV-2.
“With our different coronavirus tests and variable analysis strategies, we open up a range of testing scenarios with a Vivalytic device – from screening all the way to supporting differential diagnosis for similar symptoms,” says Marc Meier, president of Bosch Healthcare Solutions GmbH.
And development work for Covid tests on the Vivalytic is ongoing: as of early October 2020, by pooling samples together it will be possible to simultaneously evaluate five samples in one test cartridge and at a comparable speed – a world first.
This will increase available testing capacity, by enabling fully automated processing of more than 160 samples a day using a Vivalytic device.
Key Benefits of SARS-CoV-2 test on Vivalytic point of care platform
The advantages of the rapid SARS-CoV-2 test on Vivalytic lie not only in speedy analysis, but also in ease of use. A sample is taken from the nose or throat using a swab, and placed in the test cartridge. Then the cartridge, which contains all the reagents required for the test, is inserted into the Vivalytic device for automated analysis.
- Turnaround time of 39 mins from sample entry to result.
- The SARS-CoV-2 rapid test has recently received CE marking.
- The SARS-CoV-2 pooling test can run up to 5 samples on-board one single cartridge.
- Easy 4-step user-friendly process from sample entry to result. Minimal training required.
- Detection from real-time PCR from Nasopharyngeal and/or Oropharyngeal swab.
- Suitable for use in any laboratory and non-laboratory settings.
The development of the new Vivalytic PCR singleplex test is part of a research and development project funded by the German Federal Ministry of Education and Research (BMBF).
For more information please contact marketing@randox.com
RESEARCH
BIOPHARMA
CLINICAL LAB
BIOREAGENTS
Vivalytic | Test Menu
Vivalytic | Test Menu
–
Detection at the Point Of Care
Detect Infections Now
SARS-CoV-2
Respiratory
Genitourinary
Hospital Acquired Infections
Respiratory
| VIRUSES | ||
| SARS-CoV-2 (COVID-19) | Sarbecovirus (SARS, SARS like, SARS-CoV-2) | Influenza A |
| Coronavirus 229E/NL63 | Adenovirus A/B/C/D/E | Influenza B |
| Coronavirus OC43/HKUI | Enterovirus A/B/C | Rhinovirus A/B |
| Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | ||
| VIRUSES | ||
| SARS-CoV-2 (COVID-19) | ||
| VIRUSES | ||
| SARS-CoV-2 (COVID-19) | ||
| VIRUSES | ||
| Influenza A | Coronavirus OC43/HKUI | Parainfluenza virus 3 |
| Influenza B | Enterovirus A/B/C | Parainfluenza virus 4 |
| Adenovirus A/B/C/D/E | Metapneumovirus | Respiratory syncytial virus A/B |
| Bocavirus 1/2/3 | Parainfluenza virus 1 | Rhinovirus A/B/C |
| Coronavirus 229E/NL63 | Parainfluenza virus 2 | |
| BACTERIA | ||
| Bordetella parapertussis | Haemophilus influenzae | Mycoplasma pneumoniae |
| Bordetella pertussis | Legionella pneumophila | Streptococcus pneumoniae |
| Chlamydophila pneumoniae | Moraxella catarrhalis | |
| VIRUSES | ||
| Influenza A | Influenza B | Respiratory Syncytial Virus (RSV) |
| VIRUSES | ||
| Adenovirus | Respiratory syncytial virus B | Influenza B |
| Metapneumovirus | Rhinovirus A/B/C | |
| Respiratory syncytial virus A | Influenza virus A | |
| BACTERIA | ||
| Achromobacter xylosoxidans | Moraxella catarrhalis | Pseudomonas aeruginosa |
| Bordetella pertussis | Mycoplasma pneumoniae | Staphylococcus aureus |
| Burkholderia cepacia complex (21 spp) | Non-tuberculous mycobacterium (15 spp | Stenotrophomonas maltophila |
| Burkholderia Cenocepacia | Mycobacterium abscessus subgroup (4 spp) | Streptococcus pneumoniae (21spp) |
| Burkholderia multivorans | Mycobacterium avium complex (4 spp) | Streptococcus species (19 spp) |
| Chlamydia pneumoniae | Pandoraea species (5spp) | Veillonella species (3 spp) |
| Haemophilus influenza | Prevotella species (16 spp) | |
| FUNGI | ||
| Aspergillus fumigatus | Candida albicans | Exophialia dermatitidis |
| Scedosporium species (7 spp) | ||
| ANTIBIOTIC RESISTANCE MARKERS | ||
| mecA (incl MRSA) | ||
Genitourinary
| VIRUSES | |
| Neisseria Gonorrhoeae (NG) | Haemophilus Ducreyi (HD) |
| Mycoplasma Genitalium (MG) | Mycoplasma Hominis (MH) |
| Ureaplasma Urealyticum (UU) | Treponema Pallidum (TP) |
| Chlamydia Trachomatis (CT) | Herpes Simplex virus 1(HSV-1) |
| Trichomonas Vaginalis (TV) | Herpes Simplex virus 2(HSV-2) |
| BACTERIA | ||
| Citrobacter freundii | Klebsiella oxytoca | Serratia marcescens |
| Citrobacter koseri | Klebsiella pneumoniae | Staphylococcus aureus |
| Klebsiella aerogenes | Morganella morganii | Staphylococcus epidermidis |
| Enterobacter cloacae | Proteus spp. | Staphylococcus saprophyticus |
| Enterococcus faecalis | Pseudomonas aeruginosa | Streptococcus agalactiae (GBS) |
| Enterococcus faecium | Providencia rettgeri | |
| FUNGUS | ||
| Candida albicans | ||
| ANTIOBIOTIC RESISTANCE MARKERS | ||
| mecA (incl MRSA) | Trimethoprim Resistance 3 | Van A (Vancomycin Resistance A) |
| Trimethoprim Resistance 1 | Trimethoprim Resistance 4 | Van B (Vancomycin Resistance B) |
| Trimethoprim Resistance 2 | Trimethoprim Resistance 5 | |
Hospital Acquired Infections
| BACTERIA | ||
| Methicillin-resistant Staphylococcus aureus (MRSA) | Methicillin-sensitive Staphylococcus aureus (MSSA) | Methicillin-resistant coagulase-negative Staphylococci (MRCoNS) |
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
Vivalytic Testing Cartridges
VRI Array
Vivalytic
SARS-CoV-2 Rapid Test
Vivalytic | Test Cartridges
Vivalytic | Cartridges
–
Powered by Biochip Technology
Simple & Accurate POC Molecular Diagnostics
- Unique test menu covering a diverse range of respiratory, genitourinary and hospital acquired infections including SARS-CoV-2 (COVID-19)
- Multiplex technology allows for the detection of multiple targets from a single patient sample
- All reagents are on-board vivalytic cartridges
- Vivalytic cartridges are capable of target detection from multiple sample types Urine, Nasopharyngeal or Oropharyngeal Swab & Sputum
- Vivalytic cartridges are suitable for use at room temperature
- Vivalytic cartridges provide users with minimal risk contamination
Vivalytic cartridges are compact, technologically advanced Molecular Diagnostic tests utilising micro-fluidics to enable simple and accurate diagnostic testing. Vivalytic cartridges are powered by a variety of technologies, dependent upon the test application. Hi-Plex and Lo-Plex tests can be analysed on the Vivalytic. Hi-Plex tests utilise Randox patented Biochip Array Technology, enabling end-point qualitative PCR and providing multiple test results from each sample. Lo-Plex tests are based on a variety of detection methods including real-time qualitative PCR and melting curve analysis.
Randox patented Biochip Technology allows simultaneous detection of multiple targets from a single patient sample. The biochip detection system is based on a chemiluminescent signal, this is the emission of light, without heat, as a result of a chemical reaction. Each biochip is prefabricated with spatially discrete testing regions (DTR’s).
Each DTR represents an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest. The Hi-Plex capabilities of Biochip Technology eliminates the need to run multiple time consuming and sample intensive assays.
An enzyme is used to catalyse the chemical reaction of the biochip which generates the chemiluminescent signal. The light emitted from the chemiluminescent reaction that takes place in each DTR is simultaneously detected and quantified using a Charge – Coupled Device (CCD) Camera. This CCD Camera simultaneously records the light emission from all the DTRs on each biochip. The Vivalytic automatically generates a result report for all targets.
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
SARS-CoV-2 Rapid Test
VRI Array
Vivalytic
Vivalytic Test Menu
Vivalytic | SARS-CoV-2 Rapid 39 Minute Test
Vivalytic | SARS-CoV-2 Rapid 39 Minute Test
–
Detecting SARS-CoV-2 (COVID-19)
Rapidly Detecting SARS-CoV-2 (COVID-19)
- Detection from real-time PCR via Nasopharyngeal and/or Oropharyngeal swab
- The SARS-CoV-2 rapid test targets the E gene sequence for COVID-19 detection
- The SARS-CoV-2 rapid test has recently received CE marking
- Simple and easy to use analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
- Rapid turnaround time of just 39 mins from sample entry to result
- Convenient 4 step process from sample entry to results. No laboratory training required
SARS-CoV-2 (COVID-19) is a rapid real time PCR test cartridge, providing clear and concise results in a timely manner, direct at the point of care. This enables the patient to take the recommended safety precautions without delay.
In collaboration with Bosch, we are proud to release not only a rapid testing solution for the detection of SARS-CoV-2 (COVID-19) but an accelerated mass testing solution to effectively and efficiently monitor and detect viral infection from the offset with an aim of minimising the rise in infections globally. The new SARS-CoV-2 pooling test will allow users to test up to 160 samples a day and has sensitivity of 98% and a specificity of 100% – a world’s first!
Vivalytic Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.
“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
Viral Respiratory Infection Array
SARS-CoV-2 Pooling Test
Vivalytic
Vivalytic Test Menu
Vivalytic | The All in One Molecular Solution
Vivalytic | All In One Molecular Solution
–
Molecular Diagnostics at the Point of Care
Why Choose the Vivalytic?
- Fully automated, sample to answer point of care diagnostics
- Full molecular workflow consolidated into one small benchtop platform
- Unique test menu covering a diverse range of respiratory, genitourinary and hospital acquired infections including SARS-CoV-2 (COVID-19)
- Hi-Plex & Lo-Plex Capabilities. Powered by Randox Biochip Technology enabling multiple results from one patient sample
- Wireless connectivity, no peripherals required making Vivalytic a unique space-saving & hygienic solution
- Easy 4 step process from sample entry to results. No laboratory training required
Vivalytic Test Menu
| VIRUSES | ||
| SARS-CoV-2 (COVID-19) | ||
| VIRUSES | ||
| SARS-CoV-2 (COVID-19) | ||
| VIRUSES | |
| SARS-CoV-2 (COVID-19) | Sarbecovirus (SARS, SARS like, SARS-CoV-2) |
| VIRUSES | ||
| SARS-CoV-2 (COVID-19) | Sarbecovirus (SARS, SARS like, SARS-CoV-2) | Influenza A |
| Coronavirus 229E/NL63 | Adenovirus A/B/C/D/E | Influenza B |
| Coronavirus OC43/HKUI | Enterovirus A/B/C | Rhinovirus A/B |
| Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | ||
| VIRUSES | ||
| Adenovirus | Respiratory syncytial virus B | Influenza B |
| Metapneumovirus | Rhinovirus A/B/C | |
| Respiratory syncytial virus A | Influenza virus A | |
| BACTERIA | ||
| Achromobacter xylosoxidans | Moraxella catarrhalis | Pseudomonas aeruginosa |
| Bordetella pertussis | Mycoplasma pneumoniae | Staphylococcus aureus |
| Burkholderia cepacia complex (21 spp) | Non-tuberculous mycobacterium (15 spp | Stenotrophomonas maltophila |
| Burkholderia Cenocepacia | Mycobacterium abscessus subgroup (4 spp) | Streptococcus pneumoniae (21spp) |
| Burkholderia multivorans | Mycobacterium avium complex (4 spp) | Streptococcus species (19 spp) |
| Chlamydia pneumoniae | Pandoraea species (5spp) | Veillonella species (3 spp) |
| Haemophilus influenza | Prevotella species (16 spp) | |
| FUNGI | ||
| Aspergillus fumigatus | Candida albicans | Exophialia dermatitidis |
| Scedosporium species (7 spp) | ||
| ANTIBIOTIC RESISTANCE MARKERS | ||
| mecA (incl MRSA) | ||
| BACTERIA | ||
| Methicillin-resistant Staphylococcus aureus (MRSA) | Methicillin-sensitive Staphylococcus aureus (MSSA) | Methicillin-resistant coagulase-negative Staphylococci (MRCoNS) |
| VIRUSES | ||
| Influenza A | Coronavirus OC43/HKUI | Parainfluenza virus 3 |
| Influenza B | Enterovirus A/B/C | Parainfluenza virus 4 |
| Adenovirus A/B/C/D/E | Metapneumovirus | Respiratory syncytial virus A/B |
| Bocavirus 1/2/3 | Parainfluenza virus 1 | Rhinovirus A/B/C |
| Coronavirus 229E/NL63 | Parainfluenza virus 2 | |
| BACTERIA | ||
| Bordetella parapertussis | Haemophilus influenzae | Mycoplasma pneumoniae |
| Bordetella pertussis | Legionella pneumophila | Streptococcus pneumoniae |
| Chlamydophila pneumoniae | Moraxella catarrhalis | |
| VIRUSES | ||
| Influenza A | Influenza B | Respiratory Syncytial Virus (RSV) |
| VIRUSES | |
| Neisseria Gonorrhoeae (NG) | Haemophilus Ducreyi (HD) |
| Mycoplasma Genitalium (MG) | Mycoplasma Hominis (MH) |
| Ureaplasma Urealyticum (UU) | Treponema Pallidum (TP) |
| Chlamydia Trachomatis (CT) | Herpes Simplex virus 1(HSV-1) |
| Trichomonas Vaginalis (TV) | Herpes Simplex virus 2(HSV-2) |
| BACTERIA | ||
| Citrobacter freundii | Klebsiella oxytoca | Serratia marcescens |
| Citrobacter koseri | Klebsiella pneumoniae | Staphylococcus aureus |
| Klebsiella aerogenes | Morganella morganii | Staphylococcus epidermidis |
| Enterobacter cloacae | Proteus spp. | Staphylococcus saprophyticus |
| Enterococcus faecalis | Pseudomonas aeruginosa | Streptococcus agalactiae (GBS) |
| Enterococcus faecium | Providencia rettgeri | |
| FUNGUS | ||
| Candida albicans | ||
| ANTIOBIOTIC RESISTANCE MARKERS | ||
| mecA (incl MRSA) | Trimethoprim Resistance 3 | Van A (Vancomycin Resistance A) |
| Trimethoprim Resistance 1 | Trimethoprim Resistance 4 | Van B (Vancomycin Resistance B) |
| Trimethoprim Resistance 2 | Trimethoprim Resistance 5 | |
Vivalytic Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.
“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products